Z Squared is growing revenue fast enough to rank as an industry leader, but a cash-burning, sub-floor quality profile and a hard-blocked momentum gate have driven a deep drawdown that the engine treats as speculative.
Thesis pillars
- Strong Revenue Growth Leadership→Stable
- Cash Burning Quality Below Floor→Stable
- Hard Blocked Momentum Death Cross→Stable
- +1 more pillar — see the Why tab for full reasoning
Z Squared Inc. (ZSQR) Stock Analysis
Falling Knife setup
Technology · Software - Infrastructure
Sell if holding. Engine safety override at $7.03: Quality below floor (1.4 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 5.4/10. Specifically: Below-average business quality; Negative price momentum; Below long-term trend.
Z Squared Inc. (formerly Coeptis Therapeutics Holdings) is a holding company operating a biopharmaceutical division developing early-stage cell therapy platforms for cancer and autoimmune disease, including the CD38-GEAR-NK and SNAP-CAR programs, alongside a technology division... Read more
Sell if holding. Engine safety override at $7.03: Quality below floor (1.4 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 5.4/10. Specifically: Below-average business quality; Negative price momentum; Below long-term trend. Chart setup: Death cross, below all MAs, RSI 24, MACD bearish. Score 5.4/10, moderate confidence.
Passes 5/9 gates (clean insider activity, news events none recent, earnings proximity no date, semi cycle peak clear, materials cycle peak clear). Fails on weak momentum and death cross (50MA < 200MA). Suitability: speculative.
About Z Squared Inc.
About Z Squared Inc.
Z Squared Inc., operating through its Coeptis Therapeutics subsidiary, runs two distinct business lines: a biopharmaceutical division advancing early-stage cell therapy candidates such as CD38-GEAR-NK, CD38-Diagnostic, and the SNAP-CAR platform, and a technology division built around the NexGenAI Affiliates Network, an AI-driven marketing automation platform acquired in December 2024. Most biopharmaceutical programs remain in pre-clinical development, with only the in-licensed DVX201 natural killer cell therapy having reached Phase 1 trials, and the company has not disclosed material product revenue from either segment.
Z Squared's biopharmaceutical assets are built almost entirely on in-licensed technology rather than internally originated science: CD38-GEAR-NK and CD38-Diagnostic were acquired from Vy-Gen-Bio through option agreements paid for with roughly $1.75 million in cash and promissory notes, the SNAP-CAR platform is exclusively licensed from the University of Pittsburgh for an initial $75,000 fee plus royalties of 3.5% of net sales, and the DVX201 natural killer cell program and related IP were purchased from Deverra Therapeutics for approximately $570,000 in cash and 200,000 shares of common stock. Under its co-development agreement with Vy-Gen, Z Squared shares net revenues from CD38-GEAR-NK and CD38-Diagnostic 50/50 rather than retaining full economics. On the technology side, the NexGenAI platform generates revenue from managed marketing services, including lead generation, content marketing, and social media marketing, sold under the company's own brand rather than through the biopharmaceutical licensing structure.
Show full overview
Z Squared's identity is in the midst of a structural pivot that the 10-K's business description does not yet fully capture: in April 2026, Coeptis Therapeutics Holdings completed a reverse merger with a private company named Z Squared Inc., changed its own corporate name to match, and by late June 2026 had appointed a new Chief Technology Officer whose prior roles centered on immersion-cooled data center infrastructure and cryptocurrency-mining fleet management rather than cell therapy. The company also entered a binding letter of intent in April 2026 to acquire Skycore Digital LLC, a data-center operator, for up to $22.0 million in newly designated preferred stock, suggesting that Z Squared's near-term strategic center of gravity may shift toward digital infrastructure even as its legacy CD38-GEAR-NK, SNAP-CAR, and NexGenAI assets remain on the books.
See also: Technology · Software - Infrastructure
From Z Squared Inc.'s most recent 10-K filing, extracted July 6, 2026.
Recent developments
updated 2026-07-08Recent Developments — Z Squared Inc.
Latest news
- NEWS Z Squared (ZSQR) Stock Rebounds After-Hours: Here's What's Going On — benzinga Jul 8, 2026 positive
- NEWS Z Squared Raises $15.3M In Capital Under Its Standby Equity Purchase Agreement, To Advance AI Infrastructure And Acquisi — benzinga Jun 29, 2026 positive
- NEWS Z Squared Confirms Inclusion In Russell 3000 Index And Russell 2000 Index — benzinga Jun 29, 2026 positive
Generated 2026-07-08T22:24:20Z.
Thesis
Key Metrics
Quality Signals
Material Events(8-K, last 90d)
- 2026-04-30Item 5.01HIGHOn April 24, 2026, Coeptis Therapeutics Holdings completed a reverse merger with private company Z Squared Inc., which survived as a wholly owned subsidiary; Coeptis then renamed itself Z Squared Inc. effective April 27, 2026. Change-of-control event.SEC filing →
- 2026-05-22Item 5.02MEDIUMCo-CEO and director Michelle Burke resigned effective May 22, 2026, not due to any disagreement with the company; David Halabu continues as sole CEO. No board successor named yet for Burke's director seat.SEC filing →
- 2026-06-30Item 5.02LOWOn June 24, 2026, the board appointed Jeffery Harris, former CTO of digital-infrastructure company Paradox Data LLC, as Chief Technology Officer. Routine appointment, no departure involved.SEC filing →
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Rating Breakdown
2 floor-breakers·1 ceiling hit
Price action weak — below key moving averages, no momentum carry. Needs a base before trend-continuation setups apply.static
Quality below the gate floor. Component breakdown shows what dragged the score down.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Sell if holding. Engine safety override at $7.03: Quality below floor (1.4 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 5.4/10. Specifically: Below-average business quality; Negative price momentum; Below long-term trend. Chart setup: Death cross, below all MAs, RSI 24, MACD bearish. Prior stop was $6.73. Score 5.4/10, moderate confidence.
Take-profit target: $16.51 (+134.5% upside). Prior stop was $6.73. Stop-loss: $6.73.
Quality below floor (1.4 < 4.0).
Z Squared Inc. trades at a P/E of N/A (forward N/A). TrendMatrix value score: 5.0/10. Verdict: Sell.
6 analysts cover ZSQR with a consensus score of 2.2/5.
What does Z Squared Inc. do?Z Squared Inc. (formerly Coeptis Therapeutics Holdings) is a holding company operating a biopharmaceutical division...
Z Squared Inc. (formerly Coeptis Therapeutics Holdings) is a holding company operating a biopharmaceutical division developing early-stage cell therapy platforms for cancer and autoimmune disease, including the CD38-GEAR-NK and SNAP-CAR programs, alongside a technology division offering AI-powered marketing automation and robotic process automation through its NexGenAI Affiliates Network platform. Most of the company's product candidates remain pre-clinical or early Phase 1, and the company reports no material product revenue from either division in its Item 1 disclosures.